Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Le Cesne

Showing results (1-10 of 317) with videos related to

Pageof 32
Sort By:
Expert Review of Anticancer Therapy|May 4, 2013
13 years of trabectedin, 5 years of Yondelis®: what have we learnt?Axel Le Cesne
Future Oncology (London, England)|October 6, 2022
The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety dataAxel Le Cesne
Oncology|December 17, 2018
Making the Best of Available Options for Optimal Sarcoma TreatmentAxel Le Cesne
Immunotherapy|January 11, 2023
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|October 2, 2023
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|February 7, 2025
Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomasTarek Assi, Axel Le Cesne
Future Oncology (London, England)|September 15, 2016
Key messages from the BFR14 trial of the French Sarcoma GroupAnna Patrikidou, Axel Le Cesne
La Revue Du Praticien|April 25, 2006
[Diagnosis and treatment of gastrointestinal stromal tumours]Sylvie Bonvalot, Axel Le Cesne
Immunotherapy|February 16, 2024
Immune checkpoint inhibitors in follicular dendritic cell sarcomaTarek Assi, Axel Le Cesne
F1000Research|September 21, 2017
Recent advances in managing gastrointestinal stromal tumorFlorence Duffaud, Axel Le Cesne
Pageof 32

Showing results (1-10 of 317) with videos related to

Sort By:
Pageof 32
Expert Review of Anticancer Therapy|May 4, 2013
13 years of trabectedin, 5 years of Yondelis®: what have we learnt?Axel Le Cesne
Future Oncology (London, England)|October 6, 2022
The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety dataAxel Le Cesne
Oncology|December 17, 2018
Making the Best of Available Options for Optimal Sarcoma TreatmentAxel Le Cesne
Immunotherapy|January 11, 2023
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|October 2, 2023
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|February 7, 2025
Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomasTarek Assi, Axel Le Cesne
Future Oncology (London, England)|September 15, 2016
Key messages from the BFR14 trial of the French Sarcoma GroupAnna Patrikidou, Axel Le Cesne
La Revue Du Praticien|April 25, 2006
[Diagnosis and treatment of gastrointestinal stromal tumours]Sylvie Bonvalot, Axel Le Cesne
Immunotherapy|February 16, 2024
Immune checkpoint inhibitors in follicular dendritic cell sarcomaTarek Assi, Axel Le Cesne
F1000Research|September 21, 2017
Recent advances in managing gastrointestinal stromal tumorFlorence Duffaud, Axel Le Cesne
Pageof 32